- The MammaPrint 70-gene signature has a similar prognostic performance in women with early-stage invasive lobular carcinoma (ILC) or with invasive ductal carcinoma (IDC).
- The findings were presented at the 12th European Breast Cancer Conference.
Why this matters
- Chemotherapy decisions for patients with ILC remain controversial.
- Exploratory analysis of phase 3 MINDACT trial.
- Data from 5313 women who underwent surgery for early-stage breast cancer (node-negative or up to 3 positive lymph nodes) and who were risk-stratified to receive or skip adjuvant chemotherapy on the basis of both clinical risk and the MammaPrint score for genomic risk.
- Funding: Breast Cancer Research Foundation.
- Median follow-up was 8.7 years.
- MammaPrint classified 39% of the IDC group and 16% of the ILC group (10% of those with classic disease and 23% of those with variant disease) as genomically high risk for recurrence.
- 5-year rate of distant metastasis-free survival among all patients classified as genomic high risk was 92.3% (95% CI, 90.9%-93.5%) in women with IDC and 89.4% (95% CI, 78.5%-94.9%) in women with ILC.
- Exploratory analysis.